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A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year 
following hospitalization and enrollment in a disease management program 
 
Murphy TM, Waterhouse DF, James S, Casey Q, Fitzgerald E,  O’Connell E, Watson C, 
Gallagher J, Ledwidge M, McDonald K. 
 
Background 
Admission with heart failure (HF) is a milestone in the progression of the disease, often 
resulting in higher intensity medical care and ensuing readmissions. Whilst there is evidence 
supporting enrolling patients in a heart failure disease management program (HF-DMP), not 
all reported HF-DMPs have systematically enrolled patients with HF with preserved ejection 
fraction (HFpEF) and there is a scarcity of literature differentiating costs based on HF-
phenotype. 
 
Methods 
1292 consenting, consecutive patients admitted with a primary diagnosis of HF were enrolled 
in a hospital based HF-DMP and categorized as HFpEF(EF≥ 45%) or HFrEF(EF<45%). 
Hospitalizations, primary care, medications, and DMP workload with associated costs were 
evaluated assessing DMP clinic-visits, telephonic contact, medication changes over 1 year 
using a mixture of casemix and micro-costing techniques.  
 
Results 
The total average annual cost per patient was marginally higher in patients with HFrEF 
€13,011(12011,14078) than HFpEF, €12206(11009,13518). However, emergency non-
cardiovascular admission rates and average cost per patient were higher in the HFpEF vs 
HFrEF group(0.46 vs 0.31 per patient/12 months) &  €655(318,1073) vs €584(396,812).  In 
the first 3 months of the outpatient HF-DMP the HFrEF population cost more on average 
€791(764,819) vs €693(660,728). 
 
Conclusion 
4 
There are greater short-term (3-month) costs of HFrEF versus HFpEF as part of a HF-DMP 
following an admission. However, long-term (3-12month) costs of HFpEF are greater because 
of higher non-cardiovascular rehospitalisations. As HFpEF becomes the dominant form of HF, 
more work is required in HF-DMPs to address prevention of non-cardiovascular 
rehospitalisations and to integrate hospital based HF-DMPs into primary healthcare 
structures.  
 
 
Introduction: 
 
Heart failure (HF) affects over 5 million individuals in the USA with direct and indirect costs of 
more than $30 billion per annum, with costs expected to rise almost 120% to $72 billion in 
2030.1 2  A significant portion of this expenditure is related to frequent hospitalizations with a 
reported 1-month readmission rate of 25% and 1 year readmission rate of 43.9% following an 
admission with HF. 3 4 5 In order to address the high readmission rates and associated 
burgeoning financial costs, HF disease management programs (HF-DMPs) were developed 
to improve patient outcomes, reduce mortality and re-admission rates in HF patients.  
 
Whilst there is evidence to support the benefits of HF-DMPs, little data exists to assist 
clinicians and policy makers identify and cost the resources that are needed to implement the 
steps to provide optimal care. 6 7 8 9 10 11  In addition, the majority of literature regarding HF-
DMPs fails to differentiate the study populations or outcomes based on heart failure 
phenotype, despite distinct differences in the underlying pathology and 
management. 1213Furthermore, several randomized controlled trials reviewing HF-DMPs omit 
patients with preserved ejection fraction HF. 14 15 16 Subsequently, the clinical and fiscal load 
of each individual cohort is poorly defined and requires further clarification to guide 
appropriate allocation of resources. 
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Therefore, the purpose of this report is to investigate resource utilisation and cost comparing 
heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection 
fraction HFpEF during the first year following hospitalization with HF managed within a DMP.  
 
 
 
 
 
 
Methods: 
  
This is a retrospective analysis of 1292 patients followed for 1 year after admission with HF. 
Consenting, consecutive patients admitted with a primary diagnosis of HF were enrolled in a 
hospital based, HF-DMP and were categorized as HFpEF and HFrEF. (See Appendix for 
Structure of DMP) The average cost-per-case for inpatient and outpatient visit was calculated 
from the National Casemix Program, which classifies DRGs (diagnosis-related groups) based 
on the primary ICD-10 code assigned to the case, telephone contact was calculated by micro-
costing and all costs were discounted to the same year of analysis 2013. 17   
 
Analysis of Clinical Workload : 
 
The clinical workload was assessed based on five parameters:  
 
Admissions:  
 
Admissions to hospital were classified due to cause, including emergency hospitalization for 
HF, non-HF cardiovascular reasons and non-cardiovascular emergency as well as elective 
admissions. End point information was obtained from patient interview with direct entering 
onto the data base. Information was cross checked against patient medical records and the 
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admission-discharge records of the three local hospitals that provide emergency services. 
Mortality rates were also calculated.  
 
Clinic visits: 
 
Clinic visits were assessed as total number and subdivided into scheduled, including visits for 
drug titration, and unscheduled clinic visits defined as physician reviews of the patient as 
result of patient/family physician reported event.  
 
Phone contact: 
 
Total telephonic contact between the HF unit and patient and their primary carer was noted 
and subdivided into outbound calls (initiated from the HF unit and driven almost exclusively by 
protocol calls) and inbound calls (initiated by the patient and reflecting concern over potential 
clinical deterioration)  
 
Medication Titrations: 
 
Information on titration of medication was calculated from prescription notes.  
 
 
Family Physician Visits: 
 
Clinic visits were assessed as total number throughout the course of a year. 
 
The above metrics were subdivided into HFrEF and HFpEF. HFrEF was defined as those with 
left ventricular ejection fraction < 45% at initial presentation, whilst those with an ejection 
fraction > or equal to 45% were classified as HFpEF. Hospital costs were calculated using 
average casemix data weighted for type and severity of admission multiplied by the actual 
length of stay. DMP costs were calculated using a mixture of casemix and microcosting 
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techniques. For example, we took national casemix figures for HF-DMP clinic attendances 
applied to the number of scheduled and unscheduled visits and we used microcosting 
techniques to determine resource utilization of outbound and inbound telemonitoring.  All 
costs were taken from the provider perspective and discounted using 5% rate to the year of 
analysis.  
 
 
Statistical Analysis  
 
Summary data for continuous variables are presented in the form 50th percentile [25th  
percentile:75th percentile] – median [interquartile range] – unless otherwise indicated.  
Categorical variables are presented as absolute numbers and percentages. Where p-values 
are reported, they refer to t-tests (for normally distributed data), wilcoxon tests (for continuous 
non-normally distributed data) and chi-square tests (for categorical data ). Where multiple 
tests are performed on a single outcome variable, p-values have been adjusted using the 
Bonferroni method of correction. All tests are two-tailed unless otherwise indicated and the 
threshold for statistical significance is taken as 0.05. R Foundation for Statistical Computing, 
Vienna, Austria; ISBN 3-900051-07-0, (http://www.R-project.org) was used for all calculations.  
 
Results  
Population Demographics (Table 1)  
We report on 1292 survivors of hospitalization with HF managed within a DMP. The mean 
age of the cohort is 74.5 years, with a marginal dominance of male patients. The Charlson 
comorbidity index was high reflecting advanced age and a high comorbidity burden. The 
dominant HF etiology was ischemic. All patients were NYHA Class IV on admission, with 
markedly elevated natriuretic peptide levels, which while still elevated at discharge, showed a 
significant decline consistent with clinical stabilization.  
 
Sixty eight percent of the population was defined as HFrEF on admission. This cohort were 
younger and more male-dominated that the HFpEF cohort. The HFpEF cohort had a higher 
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Charlson index and hypertension was a more prevalent etiology. Atrial fibrillation was more 
commonly observed in the HFpEF cohort. B-type natriuretic peptide (BNP) was less elevated 
in HFpEF patients on admission but, as with the HFrEF group, declined significantly by the 
time of discharge.  The median length of stay in the entire cohort was 9 days with a 
statistically significant shorter hospitalization period for those with HFpEF.  
 
Clinical Workload Indices:  
 
Clinic Visits 
 
Over the three-month program duration there were 5046 clinical visits, with a mean of 3.9 
visits/patient. Total clinical visit time/patient was 132 [99:171] mins. Overall there were 4442 
scheduled visits and 604 unscheduled visits, with a rate of 0.47 unscheduled visits/patient. 
Notably, almost 30% of the total cohort required at least one unscheduled visit, with the most 
frequent use of this service in the first week post discharge (Figure 1). Overall, 19.2% of 
patients had 1 unscheduled visit, while 10.8% of patients had >1 unscheduled visits during 
this three month period.  
 
There were a greater number of total visits among those with HFrEF when compared with the 
HFpEF cohort. Those with HFrEF had 4.0 visits/patient while those with HFpEF had 3.7 
visits/patient (rate ratio (95% CI) = 1.08 (1.02,1.15); p=0.01). This difference reflects an 
increased number of scheduled visits in the HFrEF group (3.5 vs. 3.2 per patient), likely 
secondary to the increased number of medication changes in this group reflecting titration of 
disease management drugs.  Consistent with this observation was the observation that total 
clinic time was greater in those with HFrEF compared with patients with HFpEF (135 vs. 125 
mins, Wilcoxon p=0.03).  
 
When unscheduled visits are assessed, HFpEF had a similar frequency of unscheduled 
attendance to HFrEF (HFpEF 0.49 vs. HFrEF 0.46, Rate ratio p= 0.46). Within the HFpEF 
cohort, 22.5% of patients had 1 unscheduled visit and 10.7% had >1 unscheduled visits. The 
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HFrEF cohort had slightly less with 17.6% of this group having 1 unscheduled visit and 10.8% 
having >1 unscheduled visits.  
 
Phone Calls ( Supp. Figure 2) 
 
There were non-significant differences in frequency of inbound and outbound telemonitoring 
phone calls in those with HFrEF vs. those with HFpEF (inbound, HFrEF 16.9 calls/ 100 
patients / week, HFpEF had 16.1 calls/ 100 patients / week; outbound HFrEF 84.9 calls/ 100 
patients/ week, HFpEF 81.9 calls/ 100 patients / week).  
 
               Medication Changes (Supp. Table 1 )  
 
i Diuretics 
 
Ninty-two per cent of patients were prescribed diuretics with a mean dose at discharge from 
hospital of 58.7mg frusemide equivalent. Mean dose of diuretic at the end of the three-month 
program was 63.1mg frusemide eq. Overall, 55.3% of patients did not have their dose altered 
during the three-month program, while 22.5% had their first diuretic dose alteration within one 
month of discharge, 11.1% within 1-2 months and 11.1% after 2 months.  Overall, alteration 
of diuretic dose (at least one increase or decrease) occurred in 44.7% of patients with 25.8% 
having one dose change and 18.9% having >1 dose changes during the three-moth program 
duration.  
 
There was no significant difference in diuretic discharge dose between those with HFrEF vs. 
HFpEF (HFrEF: 58.4 mg, HFpEF: 59.3 mg, p>.05). At the completion of the three-month 
program, the dose of diuretic was similar between HFrEF and HFpEF. (HFrEF: 61.7 mg, 
HFpEF: 66.2 mg; p >.05) and those with HFpEF had as frequent alterations in diuretic dose 
when compared to those with HFrEF (HFrEF 0.71 vs HFpEF 0.77 per patient; p>.05). 
 
ii ACEi/ARB  
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At discharge 73.7% of the patients were prescribed ACEi with at least one dose alteration in 
ACEI  occurring in 31.9% of the population during the three months of the program, with a 
total of 621 dose adjustments. A total of 494 patients did not have their dose changed 
following in the first 3 months following discharge, 131 (18.0%) had a dosage alteration within 
a month, 70 (9.6%) within 1-2 months and 33 (4.5%) within 2-3 months. 93 patients (9.4%) 
were on ARBs at discharge. 71 of those (76.3%) did not have their dose altered within 3 
months of discharge, 15 (16.1%) had a dosage alteration within a month, 1 (1.1%) within 1-2 
months and 6 (6.5%) within 2-3 months. 
 
As anticipated, dose changes in ACEi/ARB were less common in the HFpEF group but still 
occurred in approximately 20% of those on an ACEi. When compared to patients with HFpEF, 
patients with HFrEF had, as anticipated, a higher rate of prescription of ACEi, at higher 
doses, reflecting more frequent dose titrations, than those with HFpEF.  
 
iii Beta Blockers  
Six hundred and sixty-nine patients (67.7%) were on beta blockers at discharge. 383 of these 
(57.2%) did not have their dose altered within 3 months of discharge, 141 (21.1%) had a 
dosage alteration within a month, 85 (12.7%) within 1-2 months and 60 (9.0%) within 2-3 
months. 
 
Again, dose changes in beta-blockers were less common in the HFpEF group, but still 
occurred in one third of this population. Patients with HFrEF were more frequently prescribed 
beta blockers, at higher doses than those with HFpEF.  
 
iv Aldosterone Antagonists 
Eighty-seven patients (8.8%) were prescribed an aldosterone antagonist on discharge. At 
three month follow up, 141 (12.4%) were prescribed an aldosterone antagonist. Mean dose of 
an aldosterone antagonist at three months was 24.1 mg.  When compared, there was a 
significant difference in frequency of prescription an aldosterone antagonist between those 
with HFrEF vs. HFpEF (HFrEF 24.7%; HFpEF 9.7%; p < 0.001) as well as a difference in 
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dose of an aldosterone antagonist between the groups  (HFrEF 24.04mg; HFpEF 27.8mg; 
p<0.01)  
 
Readmission and Mortality Event Rate (Table 2) 
 
Overall the readmission rates in HFpEF were higher than HFrEF over the 12 months follow 
up (0.99 vs 0.858 per patient). The ADHF and emergency cardiovascular readmission rates 
over 12 months follow up were similar for HFpEF as HFrEF (0.31 vs. 0.28 per patient), as 
were mortality rates (0.12 vs. 0.13 per patient). However, emergency non-cardiovascular 
admission rates were notably higher in the HFpEF vs HFrEF group (0.46 vs 0.31 per patient 
over 12 months). 
 
Cost Analysis (Table 3, Figure 2) 
 
The total average cost per patient was higher in patients with HFrEF €13,011 (12011, 14078) 
than HFpEF, €12206 (11009,13518) with a significant proportion of the total cost attributed to 
the index admission.  
 
Readmission cost per patient with HFpEF was an average of €5396 (4390, 6494) versus 
€4287 (3574,5042) for HFrEF.  This is explained by higher average cost per patient for 
readmission for non-cardiovascular emergencies among  patients with HFpEF than HFrEF.  
 
The average cost per patient, attributed to the clinical workload of the HF-DMP, was greater 
in patients with HFrEF than HFpEF, costing €8.78 per day versus €7.70 during a 90 day 
intensive DMP and €2.74 versus €2.16 per day for the remaining 9 months. The majority of 
this cost was due to scheduled and titration visits. 
 
The annual clinical workload cost of a HF-DMP was approximately 11% of the total annual 
average cost per HF patient, with the majority of the total expenditure allocated to 
hospitalizations, mainly the index admission and subsequent readmissions.  
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Discussion:  
 
Multiple studies have demonstrated that disease management programs significantly reduce 
mortality and re-hospitalizations amongst patients with HF.18 19 20 21 However, not all reported 
HF-DMPs routinely include HFpEF patients and few data exist to assist clinicians and policy 
makers identify the resources that are needed to implement the steps to provide this form of 
care.  In addition, there is a dearth of data comparing workload intensity between HFpEF & 
HFrEF specifically, an important issue given the increasing number of HFpEF patients 
admitted to hospital with acute decompensated heart failure and at risk for further events.22 23 
Responding to these deficiencies in the literature, this paper presents detailed information on 
the clinical and financial landscape of HF and associated outcomes of patients managed 
within a structured cardiology led disease management program.  
 
Assessment of workload comprised analysis of three metrics of patient interaction reflective of 
scheduled and unscheduled activity. Clinic volume, as anticipated, was dominated by 
scheduled visits as mandated by the programmatic follow up post discharge.  However, there 
was an evident need to provide immediate same day review for features suggestive of 
emerging clinical deterioration, with 30% of the population requiring same-day review within 
the first three months post discharge. Approximately 10% required this service on more than 
one occasion and the most frequent use was in the first week post discharge. It is also 
noteworthy that this unscheduled service was required equally for those with HFpEF and 
HFrEF. It is likely that this service was central in achieving a low rate of readmission, and is 
consistent with a previous observation from our unit that demonstrated that in 72% of such 
presentations rehospitalization could be prevented. 24  
 
A similar observation was made in regard to telephone contact between the patient and the 
HF unit. The majority of calls were protocol-driven outbound calls but there was a steady 
weekly use of the inbound call facility of approximately 15% of call volume throughout the 
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duration of the program. This again reflecting the need to provide immediate response to the 
patient, family or general practitioner on matters related to the clinical stability. 
 
Drug dose alteration was also a major contributor to workload within the initial months post 
discharge.  As anticipated, adjustment in ACEi/ARB and Beta –Blocker therapy was more 
common in the HFrEF cohort. However, the single most frequent dose alteration occurred in 
the diuretic dose and was required as often in the HFpEF population as in the HFrEF group, 
underlying the equivalence in clinical instability in the two cohorts.  
 
Cost analysis, based on the in-depth assessment of workload and readmission figures using 
a mixture of casemix and microcosting approaches, demonstrated a marginal increase in cost 
in the care of the HFrEF patient over a period of one year including the index admission. This 
is explained by the longer length of stay of the index admission and the higher scheduled 
clinic volume in this population.  It is noteworthy however, that the HFpEF population 
accumulated a greater number of emergency non-cardiovascular admissions. This would be 
expected from this population which was older and more frail than the HFrEF cohort and 
consistent with other data sets.25   
 
The HF-DMP is designed to help transition patients through the “at risk” stage post hospital 
discharge and facilitate continued close clinical observation, ongoing education on self care 
and titration of medication with an aim of reducing hospital readmission and improving long 
term outcome.  Increasing focus on the importance of readmissions has developed as a result 
of the penalty system for readmission within 30 days of discharge in the United States.  The 
data presented herein, underline the relative low cost of an intensive DMP compared to the 
costs of admission that the service is designed to prevent. 
 
In transiting patients to a zone of relative clinical stability post discharge this data also 
underlines the need to enroll patients with HFpEF into the DMP.  Thorough analysis of 
unscheduled clinic visit frequency, use of inbound phone calls and importantly the equal need 
to adjust diuretics in this cohort suggests that this population pose as great a HF challenge as 
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patients with HFrEF. However, the data also demonstrate an increased susceptibility of the 
HFpEF patient to non-CV emergency admission and points towards a need for a DMP to 
consider close clinical interaction with other medical specialties and indeed social and 
community services. 
 
In interpreting these data several issues need to be taken into consideration. It is important to 
note that the data presented here are observational and from a single centre within one 
healthcare system. Nonetheless, given the characteristics of the population, consistent with 
other cohorts internationally, we feel the detailed information provided is of value outside of 
Ireland and will help inform unit development internationally. Secondly the analysis of 
medication use in the HFrEF cohort does demonstrate modest use of aldosterone antagonists 
during the first three months post–discharge. This reflects the fact that many of these patients 
would have gone through this three-month period before use of these agents would have 
become standard. 
 
In summary, the workload associated with a disease management program following patient 
discharge from hospital is intense, and requires a flexibility of approach to help avoid re-
hospitalization. There are greater short-term (3 month) costs associated with HFrEF versus 
HFpEF as part of a HF-DMP following an index admission. However, longer term (3-12 
month) costs of HFpEF are greater because of higher non-cardiovascular re-hospitalisations. 
As HFpEF becomes the dominant form of community HF, more work is required in HF-DMPs 
to address prevention of non-cardiovascular rehospitalisations and to integrate hospital based 
HF-DMPs into primary care healthcare structures.  
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Table 1: Population Demographics 
  All (n=1292)   HFrEF (n=879)   HFpEF (n=413) 
Age, median[IQR] years 74.5 [65.8:81.2]   
72 
[62.9:79.6]   
78.9 
[71.6:84.4]*** 
Male, n (%) 759 (58.7%)  574 (65.3%)  185 (44.8%)*** 
BMI, median[IQR] kg/m2 27.2 [23.8:31.1]  
26.5 
[23.4:30.6]  28 [25.2:31.9]** 
SBP, median [IQR] mmHg 122 [110:138]  
120 
[106:134]  
130 
[116:144]*** 
Charlson score, mean (sd) 6 [5:7]  6 [5:7]  7 [6:8]*** 
      
Heart Failure Etiology, n (%)      
Ischemic 571 (46.9%)  418 (50.2%)  153 (39.7%)** 
Hypertension 591 (45.7%)  351 (39.9%)  240 (58.1%)*** 
Valvular 129 (10.6%)  68 (8.2%)  61 (15.8%)*** 
Idiopathic 141 (11.6%)  114 (13.7%)  27 (7%)** 
Alcohol/Drugs 85 (7.0%)  80 (9.6%)  5 (1.3%)*** 
Lab results, median [IQR]      
Admission BNP, pg/mL 790 [427:1400]  
894 
[485:1502]  
602 
[398:1185]*** 
Discharge BNP, pg/mL 443 [224:818]  
502 
[263:906]  
349 
[185:617]*** 
Baseline Hemoglobin, g/dL 12.7 [11.3:14.2]  
12.9 
[11.6:14.4]  
12.1 
[10.7:13.4]*** 
Baseline Creatinine, µmol/L 104 [85.5:132]  103 [86:129]  106 [84:142] 
Baseline Urea, mmol/L 8.5 [6.4:11.8]  
8.2 
[6.3:11.2]  9.2 [6.7:13.3]** 
ECG, n (%)      
LBBB 300 (23.2%)  253 (28.8%)  47 (11.4%)*** 
A. Fib. 556 (43%)  349 (39.7%)  207 (50.1%)** 
Length of Stay (Index admission), median [IQR] 
days 9 [6:15]  10 [6:15]  8 [5:14]** 
17 
* p < .05, ** p < .01, *** p < .001 
NOTE: Percentages are calculated using only those patients with data available for that variable. 
IQR – Interquartile range, BMI- Body mass index, SBP- Systolic Blood Pressure, sd- standard 
deviation, BNP -  B-Type naturetic peptide, ECG- electrocardiogram, LBBB- Left Bundle Branch 
Block, A.Fib- Atrial Fibrillation. 
 
Table 2: 
Event Count and Event rate per Patient /Year 
 HFrEF (n=879) HFpEF (n=413) 
All Admissions, (Event rate per 
patient/year) 
754, (0.858) 409, (0.99) 
ADHF 152, (0.173) 91, (0.22) 
Death 117, (0.133) 51, (0.123) 
Elective CV 43, (0.049) 9 (0.022) 
Elective non-CV 58 (0.066) 21 (0.051) 
Emergency non ADHF CV 94, (0.107) 38, (0.092) 
Emergency non-CV 276, (0.314) 191, (0.462) 
Other 14 (0.016) 8, (0.020) 
Emergency CV and ADHF 246, (0.280) 129, (0.314) 
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Table 3: Average cost per-patient in first year. 
Average cost per-patient Euros*(95% 
CI) HFrEF (n=879) HFpEF (n=413) 
   
Index Admission (LOS based) 7660 (7047,8354) 6302 (5673,7004) 
   
Readmission Costs 4287 (3574,5042) 5396 (4390,6494) 
ADHF 1150 (835,1526) 1150 (773,1571) 
Death 116 (63,186) 73 (32,133) 
Elective CV 134 (51,265) 32 (5,77) 
Elective non-CV 216 (115,351) 79 (33,135) 
Emergency CV 584 (396,812) 655 (318,1073) 
Emergency non-CV 2039 (1528,2627) 3386 (2631,4213) 
Other 47 (16,89) 21 (3,48) 
   
DMP Clinical Workload (0-3m) 791 (764,819) 693 (660,728) 
Unscheduled  83 (72,94) 80 (67,94) 
Scheduled (including Titration) 617 (594,640) 528 (501,556) 
Telephone (outbound)** 77 (75,79) 71 (68,74) 
Telephone (inbound)** 15 (14,16) 14 (13,16) 
   
DMP Clinical Workload (3-12m) 751 (701,802) 593 (533,655) 
Unscheduled  73 (62,86) 78 (62,96) 
Scheduled (including Titration) 643 (600,688) 485 (435,537) 
Telephone (outbound)** 20 (17,23) 18 (15,22) 
Telephone (inbound)** 14 (12,16) 11 (8,13) 
   
Medications 596 (579,613) 527 (505,550) 
GP visits 594 (582,608) 569 (551,587) 
   
All Costs 13011 (12011,14078) 12206 (11009,13518) 
* Inflated/Discounted to end-of-2011 using 5% interest rate. **Based on subsample with 
detailed data n = 383. 
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Figure 1. Kaplan-Meier graph demonstrating time to first Unscheduled Clinic Visit post 
discharge 
 
 
Figure 2 
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Appendix: Structure of SVUH DMP 
 
St Vincent’s Healthcare Group Heart Failure Disease Management Programme  
 
Patients admitted with a primary diagnosis of HF are assessed by our HF cardiologists and 
transferred to the cardiology service for further management. Patients are excluded from 
enrolment to our service only if they or a family member so wish, if suffering from a terminal 
illness, have dementia to a level where the patient cannot take part in self-care or are resident 
outside our catchment area.  Management includes complete work up of the cause of HF, 
assessment of the likely precipitant of admission and initiation of appropriate therapy. Once 
clinically improved, comprehensive one-on-one education with the patient is initiated regarding 
standard self-care issues. Contact is also made with the next of kin for education on what to 
expect on discharge and how to recognise features of decompensation. Discharge planning is 
initiated when the patient is deemed euvolaemic, or as near to this state as can be effectively 
achieved. 
 
The outpatient programme is run from a chronic ambulatory care facility, which provides 
scheduled and unscheduled clinic access Monday to Friday 9am -5pm and unscheduled 
access at weekends through the on-call cardiology service in the hospital. All patients have 
three scheduled assessment visits during the 3-month period post discharge; within two weeks 
of discharge (exact timing determined by clinical stability on discharge), and again at 6 weeks 
and 12 weeks. Nurse-initiated phone consultations (outbound calls) are made to the patients 
within 48-hours of hospital discharge and then weekly for 12 weeks except on clinic visit weeks. 
The purpose of these calls is to assess well-being and address any patient concerns. 
Additionally, these outbound calls provide an opportunity for our HF nurse specialists to engage 
with the patient on matters such as medication adherence, self-care, body weight 
measurement, exercise and adherence to any dietary restrictions. 
 
Patients, their carers or general practitioners can contact the unit outside of these scheduled 
contacts for assistance in management of features suggestive of emerging clinical 
21 
deterioration. These calls are triaged by a nurse specialist and decision made to manage 
remotely or review the patient at the clinic that day if indicated  (unscheduled clinic visit).  At 
weekends and public holidays, patients and carers have a number to call to access the on-call 
cardiology medical staff in our department who provided the same service as outlined above, 
including clinical review if needed at the weekend. 
 
At completion of the 12-week programme, patients are reassessed and categorised as either 
high or low risk for future HF events. High-risk status is a decision made by the consultant in 
charge and influenced by event history since discharge and B-type natriuretic peptide (BNP) 
level at three months (BNP > 300pg/ml considered high risk). Low risk patients have care 
transferred back to the primary care physician. High-risk patients have continued close follow 
up in the DMP. All patients irrespective of risk status are seen at annual intervals for clinical 
and self care reassessment.  
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